French
DeutschRelatlimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Lymphocyte activation gene-3 (LAG-3) |
| Clinical data | |
| Other names | BMS-986016, relatlimab-rmbw |
| License data |
|
| Routes of administration | Intravenous |
| Drug class | Antineoplastic |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6472H9922N1710O2024S38 |
| Molar mass | 145288.79 g·mol−1 |
Relatlimab is a monoclonal antibody designed for the treatment of melanoma.[3][4] It is used in combination with nivolumab to treat melanoma.[2][5]
Relatlimab is a Lymphocyte activation gene-3 (LAG-3) inhibitor.[2][5] It is under development by Bristol-Myers Squibb.[2][5] It is made using Chinese hamster ovary cells.[2]
History
[edit]As of 2018[update], relatlimab is undergoing Phase II/III trials.[6]
The combination nivolumab/relatlimab (Opdualag) was approved for medical use in the United States in March 2022.[2][5]
Names
[edit]Relatlimab is the United States Adopted Name (USAN) and the international nonproprietary name (INN).[7][8][9]
References
[edit]- ^ "Notice: Multiple additions to the Prescription Drug List (PDL) [2023-12-22]". Health Canada. 22 December 2023. Retrieved 3 January 2024.
- ^ a b c d e f "Opdualag- nivolumab and relatlimab-rmbw injection". DailyMed. 18 March 2022. Retrieved 22 March 2022.
- ^ Cavagnaro JA, Cosenza ME, eds. (2021). Translational Medicine: Optimizing Preclinical Safety Evaluation of Biopharmaceuticals. Boca Raton, Florida: CRC Press. ISBN 978-1-00-047185-4.
- ^ Robert C (December 2021). "LAG-3 and PD-1 blockade raises the bar for melanoma". Nature Cancer. 2 (12): 1251–3. doi:10.1038/s43018-021-00276-8. PMID 35121906. S2CID 245407697.
- ^ a b c d "U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma" (Press release). Bristol Myers Squibb. 18 March 2022. Retrieved 19 March 2022 – via Business Wire.
- ^ Clinical trial number NCT03704077 for "An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma" at ClinicalTrials.gov
- ^ "Relatlimab". American Medical Association. Retrieved 22 March 2022.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Relatlimab, American Medical Association.
- ^ World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information. 33 (1). hdl:10665/330896.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |